180 Life Sciences (ATNF) Competitors $2.13 -0.16 (-6.99%) Closing price 04:00 PM EasternExtended Trading$2.28 +0.15 (+6.81%) As of 06:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ATNF vs. LGVN, CLDI, NAII, RLMD, RVPH, FNCH, VYNE, CING, BLRX, and MEIPShould you be buying 180 Life Sciences stock or one of its competitors? The main competitors of 180 Life Sciences include Longeveron (LGVN), Calidi Biotherapeutics (CLDI), Natural Alternatives International (NAII), Relmada Therapeutics (RLMD), Reviva Pharmaceuticals (RVPH), Finch Therapeutics Group (FNCH), VYNE Therapeutics (VYNE), Cingulate (CING), BioLineRx (BLRX), and MEI Pharma (MEIP). These companies are all part of the "pharmaceutical products" industry. 180 Life Sciences vs. Its Competitors Longeveron Calidi Biotherapeutics Natural Alternatives International Relmada Therapeutics Reviva Pharmaceuticals Finch Therapeutics Group VYNE Therapeutics Cingulate BioLineRx MEI Pharma 180 Life Sciences (NASDAQ:ATNF) and Longeveron (NASDAQ:LGVN) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, institutional ownership, dividends, risk, profitability, analyst recommendations, valuation and media sentiment. Do analysts prefer ATNF or LGVN? Longeveron has a consensus price target of $8.67, indicating a potential upside of 412.82%. Given Longeveron's stronger consensus rating and higher possible upside, analysts clearly believe Longeveron is more favorable than 180 Life Sciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score 180 Life Sciences 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Longeveron 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.25 Do insiders and institutionals believe in ATNF or LGVN? 4.1% of 180 Life Sciences shares are owned by institutional investors. Comparatively, 10.0% of Longeveron shares are owned by institutional investors. 38.2% of 180 Life Sciences shares are owned by insiders. Comparatively, 11.2% of Longeveron shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Which has stronger valuation & earnings, ATNF or LGVN? 180 Life Sciences has higher earnings, but lower revenue than Longeveron. Longeveron is trading at a lower price-to-earnings ratio than 180 Life Sciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio180 Life SciencesN/AN/A-$6.17M-$14.76-0.14Longeveron$2.39M10.56-$15.97M-$6.28-0.27 Which has more volatility and risk, ATNF or LGVN? 180 Life Sciences has a beta of 0.22, indicating that its share price is 78% less volatile than the S&P 500. Comparatively, Longeveron has a beta of 0.21, indicating that its share price is 79% less volatile than the S&P 500. Does the media favor ATNF or LGVN? In the previous week, 180 Life Sciences and 180 Life Sciences both had 2 articles in the media. 180 Life Sciences' average media sentiment score of 1.38 beat Longeveron's score of 0.00 indicating that 180 Life Sciences is being referred to more favorably in the media. Company Overall Sentiment 180 Life Sciences Positive Longeveron Neutral Is ATNF or LGVN more profitable? 180 Life Sciences has a net margin of 0.00% compared to Longeveron's net margin of -760.72%. Longeveron's return on equity of -85.07% beat 180 Life Sciences' return on equity.Company Net Margins Return on Equity Return on Assets 180 Life SciencesN/A -147.34% -77.00% Longeveron -760.72%-85.07%-70.74% SummaryLongeveron beats 180 Life Sciences on 9 of the 15 factors compared between the two stocks. Get 180 Life Sciences News Delivered to You Automatically Sign up to receive the latest news and ratings for ATNF and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ATNF and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ATNF vs. The Competition Export to ExcelMetric180 Life SciencesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$12.87M$3.06B$5.67B$9.49BDividend YieldN/A2.44%4.05%4.00%P/E Ratio-0.1420.8627.9419.95Price / SalesN/A246.06396.5882.68Price / CashN/A41.9636.1958.45Price / Book0.738.308.635.82Net Income-$6.17M-$55.19M$3.24B$258.42M7 Day Performance16.39%5.07%3.22%1.94%1 Month Performance140.14%17.61%10.72%12.02%1 Year Performance-5.33%7.03%34.94%20.80% 180 Life Sciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ATNF180 Life Sciences1.4779 of 5 stars$2.13-7.0%N/A+0.4%$12.87MN/A-0.147Positive NewsEarnings ReportLGVNLongeveron2.799 of 5 stars$1.42flat$8.67+510.3%-40.2%$21.20M$2.23M-0.2320CLDICalidi Biotherapeutics0.6578 of 5 stars$0.58-23.8%N/A-56.5%$21.03MN/A0.0038Gap UpNAIINatural Alternatives International0.6266 of 5 stars$3.40-2.6%N/A-37.0%$21.01M$125.48M-2.45290Positive NewsRLMDRelmada Therapeutics4.5457 of 5 stars$0.63+2.9%$5.00+696.8%-82.0%$20.83MN/A-0.2510RVPHReviva Pharmaceuticals2.724 of 5 stars$0.43+9.7%$9.00+1,996.4%-59.9%$20.61MN/A-0.545High Trading VolumeFNCHFinch Therapeutics GroupN/A$12.75flatN/A+866.9%$20.48MN/A-1.45190VYNEVYNE Therapeutics2.1933 of 5 stars$1.33-6.3%$6.25+369.9%-30.6%$20.23M$500K-1.3430High Trading VolumeCINGCingulate2.5934 of 5 stars$4.73+8.7%$26.00+449.7%+1,437.0%$20.08MN/A-0.5620BLRXBioLineRx2.0608 of 5 stars$4.70flat$26.00+453.2%-85.9%$20.04M$22.34M-0.5340MEIPMEI Pharma1.7254 of 5 stars$2.94+9.3%N/A+69.9%$19.58MN/A-0.62100Gap UpHigh Trading Volume Related Companies and Tools Related Companies LGVN Competitors CLDI Competitors NAII Competitors RLMD Competitors RVPH Competitors FNCH Competitors VYNE Competitors CING Competitors BLRX Competitors MEIP Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ATNF) was last updated on 7/24/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredElon Just Fired the IRS Agents Targeting Your SavingsElon Musk just fired 6,700 IRS agents — and exposed a war on your retirement. While D.C. scrambles to regai...Priority Gold | SponsoredFREE GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...GoldCo Precious Metals | SponsoredTreasury Secretary Bessent Is Betting Big on GoldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredWhy Elon put $51 million into thisA single U.S. company has started producing a “miracle metal” once locked in research labs. Now? They’re qu...True Market Insiders | SponsoredBitcoin Beats Gold — But This Coin Could Beat Them BothBitcoin just hit a record high—but it’s not the top crypto play right now. Crypto analyst Juan Villaverde, ...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding 180 Life Sciences Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share 180 Life Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ATNF Stock Alerts